Advances in the surgical treatment of esophageal cancer since 1965. Issue 3 (14th April 2020)

• Record Type: Journal Article
• Authors: Matsubara, Hisahiro
• Is Part Of: Annals of gastroenterological surgery. Volume 4:Issue 3(2020)
• Page Start: 243
• Page End: 249
• Publication Date: 2020-04-14
• Subjects: development -- esophageal cancer -- history -- surgical treatment; Digestive organs -- Surgery -- Periodicals; 617.43
• DOI: 10.1002/ags3.12332
• Languages: English
• ISSNs: 2475-0328

Abstract

Abstract: In Japan, the treatment of esophageal cancer has undergone significant development since the Japanese Society for Esophageal Diseases was established in 1965 by Doctors Komei Nakayama, Shigetsugu Katsura, and Ichiro Akakura. When the Society was established, surgery was the first‐line treatment for esophageal cancer. Since then, the Society has been led by three successive chairpersons—Doctors Katsura, Nakayama, and Satoh. Over this time, surgery‐related mortalities declined to 5%‐6% because of the rapid improvements in surgical technique. Beginning in 1980, the bilateral cervical lymph node dissection technique gained attention, and favorable long‐term outcomes were gradually reported. A nationwide questionnaire survey, conducted by the Society in 1990, showed that more favorable long‐term outcomes were achieved by following the three‐field lymph node dissection technique than by following the two‐field lymph node dissection technique. Since then, the three‐field lymph node dissection technique has been recognized and widely used as the standard surgical procedure for treating esophageal cancer. After clinical studies examined the utility of various pre‐ and postoperative adjunctive therapies in outcome improvements, preoperative chemotherapy was recognized as the standard treatment in the therapy guidelines. Additionally, less invasive surgical methods have been developed, including endoscopic and robot‐assisted surgeries, which are applied in general practice now. However, unresectable and recurrent esophageal cancers remain difficult to treat, and additional treatments should be developed.